Monthly Archives: January 2006

Recent Regulatory Changes in Antidepressant Labels: Implicatons of Activation (2006)

More focus is needed on the risk of activation or stimulation as described in the new class of warnings from the Food and Drug Administration, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania and other unusual changes of behavior, worsening of depression and suicidal ideation. recentregulatory.pbreggin.2006.pdf

Read More

Drug Company Suppressed Data on Paroxetine-Induced Stimulation (2006)

Paxil Special Report III: The third special report in a series providing excerpts from Dr. Breggin’s 1999 product liability report in the CA case of Lacuzong v. GlaxoSmithKline, alleging that Paxil (paroxetine) caused a double murder and suicide. Ethical Human Psychology and Psychiatry 8 (2006) 255-263. Peter Breggins Paxil Special Report III.pdf

Read More